Zobrazeno 1 - 4
of 4
pro vyhledávání: '"Cathy S. Wang"'
Autor:
George Tang, Eric Sanchez, James R. Berenson, Abigail Gillespie, Cathy S Wang, Mingjie Li, Haiming Chen
Publikováno v:
Leukemia Research. 57:45-54
Oprozomib (OPZ or ONYX 0912) is an irreversible, orally administered proteasome inhibitor (PI) and an analog of carfilzomib. We set out to determine the anti-angiogenic effect of OPZ using the choriollantoic membrane/feather bud (CAM/FB) model and it
Autor:
Brian Zahab, Haiming Chen, Nicole Ng, Sean Bujarski, Cathy S Wang, Edward J Tanenbaum, George Tang, Ning Xu, Jasmin Cao, Tara Hekmati, Eric Sanchez, James R. Berenson, Mingjie Li, Camilia Soof
Publikováno v:
Blood. 132:1910-1910
Introduction: Ruxolitinib (RUX) is an inhibitor of the Janus kinase family of protein tyrosine kinases (JAKs) that is effective for the treatment of myeloproliferative diseases. Immunomodulatory drugs including lenalidomide (LEN) and corticosteroids
Autor:
George Tang, Cathy S Wang, Mingjie Li, Eric Sanchez, James R. Berenson, Haiming Chen, Puja K. Mehta
Publikováno v:
Blood. 128:3297-3297
Introduction: Several studies have demonstrated constitutive activation of the JAK-STAT pathway in MM through dysregulated signaling of cytokines such as IL-6. In addition to its crucial role in promoting the growth, proliferation and survival of mye
Autor:
Thomas J. Greshock, Kenneth A. Miller, Mingjie Li, Haiming Chen, Eric Sanchez, James R. Berenson, Cathy S. Wang, Mengyin Hu, Benjamin Bonavida, James E. Bradner, Jing Shen, Crystal Leung, Jeffrey A. Steinberg, Albert A. Bowers, Nathan West, Tenaya L. Newkirk, Zhi-Wei Li, Robert M. Williams
Publikováno v:
Blood. 114:4925-4925
Abstract 4925 Multiple myeloma (MM) remains an incurable malignancy. Therefore, there is a need for the development of new agents to improve the survival for these patients. Histone acetylation, which is controlled by the balanced activities between